Education
About Us
Working with TipRanks
Follow Us
HeartBeam (BEAT)
NASDAQ:BEAT
BEAT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.91 - $3.48
Previous CloseN/A
Volume12.23K
Average Volume (3M)101.71K
Market Cap
$39.46M
Enterprise Value$37.24M
Total Cash (Recent Filing)$3.26M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Nov 06, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding34,311,590
10 Day Avg. Volume102,883
30 Day Avg. Volume101,709
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.69K
Enterprise Value/Ebitda-1.81
Forecast
1Y Price Target
$8.00Price Target Upside529.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Product DevelopmentHeartBeam is focused on applying AI to develop deep learning algorithms, further improving diagnostic accuracy and the value of the offering.
Regulatory ApprovalsHeartBeam’s proprietary system for arrhythmia assessment received 510(k) clearance from the FDA.
Strategic CollaborationsA strategic collaboration was signed with AccurKardia to add AccurECG™ algorithm to HeartBeam’s device, facilitating quicker diagnosis and faster access to clinical care.
Bears Say
Commercial Launch ChallengesHeartBeam is well prepared for a pilot commercial launch and a full launch in 2026.
Financial ExpensesCash used in operating activities was $4.5M, indicating significant expenses in the first quarter.
HeartBeam News
BEAT FAQ
What was HeartBeam’s price range in the past 12 months?
HeartBeam lowest stock price was $0.91 and its highest was $3.48 in the past 12 months.
What is HeartBeam’s market cap?
HeartBeam’s market cap is $39.46M.
When is HeartBeam’s upcoming earnings report date?
HeartBeam’s upcoming earnings report date is Nov 06, 2025 which is in 68 days.
How were HeartBeam’s earnings last quarter?
HeartBeam released its earnings results on Aug 13, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.01.
Is HeartBeam overvalued?
According to Wall Street analysts HeartBeam’s price is currently Undervalued.
Does HeartBeam pay dividends?
HeartBeam does not currently pay dividends.
What is HeartBeam’s EPS estimate?
HeartBeam’s EPS estimate is -0.12.
How many shares outstanding does HeartBeam have?
HeartBeam has 34,311,590 shares outstanding.
What happened to HeartBeam’s price movement after its last earnings report?
HeartBeam reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went down -7.5%.
Which hedge fund is a major shareholder of HeartBeam?
Currently, no hedge funds are holding shares in BEAT
HeartBeam Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (529.92% Upside)
$8.00 (529.92% Upside)
Blogger Sentiment
Bullish
BEAT Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.53%
12-Months-Change
Fundamentals
Return on Equity
-315.70%
Trailing 12-Months
Asset Growth
-40.93%
Trailing 12-Months
Company Description
HeartBeam
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
BEAT Company Deck
BEAT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights significant progress in regulatory approvals, commercial readiness, and strategic cash management, alongside industry recognition. However, challenges remain with pending FDA clearance and cash constraints.View all BEAT earnings summariesTechnical Analysis
Ownership Overview
3.59% Insiders
3.01% Mutual Funds
3.24% Other Institutional Investors
87.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---